Skip to main content

Coronavirus

15
Pipeline Programs
26
Companies
22
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
2
5
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
350%
Vaccine
350%
+ 26 programs with unclassified modality

Competitive Landscape

26 companies ranked by most advanced pipeline stage

Equillium
EquilliumCA - La Jolla
1 program
1
EQ001Phase 3
Biocon
BioconIndia - Bangalore
1 program
1
EQ001Phase 31 trial
Active Trials
NCT04605926Withdrawn0Est. Jun 2021
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
2 programs
1
1
bamlanivimab 7000mgPhase 2/3
EIDD-2801Phase 11 trial
Active Trials
NCT04392219Completed130Est. Aug 2020
Prevail Therapeutics
1 program
1
bamlanivimab 7000mgPhase 2/3
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
bamlanivimab 7000mgPhase 2/3
Sagent Pharmaceuticals
Sagent PharmaceuticalsIL - Schaumburg
1 program
1
bamlanivimab 7000mgPhase 2/3
Synairgen
SynairgenUK - Southampton
1 program
1
bamlanivimab 7000mgPhase 2/3
Syndax Pharmaceuticals
1 program
1
SNDX-6352Phase 21 trial
Active Trials
NCT04415073Terminated1Est. Jul 2020
Senhwa Biosciences
Senhwa BiosciencesCA - San Diego
1 program
1
SilmitasertibPhase 2Small Molecule1 trial
Active Trials
NCT04668209Terminated31Est. Oct 2022
AbelZeta Pharma
AbelZeta PharmaChina - Shanghai
2 programs
1
1
Mesenchymal stem cell exosomesPhase 1/21 trial
MSCs-derived exosomesPhase 11 trial
Active Trials
NCT04276987Completed24Est. Jul 2020
NCT04602104Completed18Est. Jan 2023
Sandoz
SandozAustria - Kundl
1 program
1
RuxolitinibPhase 1/2Small Molecule1 trial
Active Trials
NCT04581954Completed185Est. Sep 2023
Ridgeback Biotherapeutics
1 program
1
EIDD-2801Phase 1
Osivax
OsivaxFrance - Lyon
1 program
1
OVX033Phase 11 trial
Active Trials
NCT06128382Completed48Est. Nov 2024
CureVac
CureVacGermany - Tübingen
4 programs
CVnCoV 6 μgPHASE_21 trial
CVnCoV VaccinePHASE_3Vaccine1 trial
CVnCoV VaccinePHASE_3Vaccine1 trial
CVnCoV VaccinePHASE_3Vaccine1 trial
Active Trials
NCT04515147Completed668Est. Feb 2022
NCT04860258Terminated129Est. Sep 2021
NCT04674189Completed2,357Est. Jun 2022
+1 more trials
Gylden Pharma
Gylden PharmaUK - Abingdon
2 programs
LD Vehicle-GNPPHASE_11 trial
PepGNP-COVID19PHASE_1_21 trial
Active Trials
NCT05113862Completed26Est. Sep 2022
NCT05633446Not Yet Recruiting110Est. Dec 2026
Innovation Pharmaceuticals
1 program
Aerosol BoxN/A1 trial
Active Trials
NCT04880668Completed122Est. Dec 2021
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
COVID-19 Community Research PartnershipN/A1 trial
Active Trials
NCT04342884Completed61,410Est. May 2022
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Investigational IVD for coronavirusesN/A1 trial
Active Trials
NCT07221097Recruiting1,500Est. Aug 2026
Alliance Pharmaceuticals
1 program
Observation of patients with known, suspected, or at risk for COVID-19 infectionN/A1 trial
Active Trials
NCT04321811Completed5,000Est. Mar 2021
Akari Therapeutics
1 program
The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19N/A1 trial
Active Trials
NCT04453527Completed72Est. May 2021
Aytu BioPharma
Aytu BioPharmaDENVER, CO
1 program
UV Light TreatmentN/A1 trial
Active Trials
NCT04572399Completed5Est. Dec 2020
Celularity
CelularityFLORHAM PARK, NJ
1 program
CYNK-001PHASE_1_21 trial
Active Trials
NCT04365101Terminated7Est. Feb 2023
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
RuxolitinibPHASE_1_2Small Molecule
Bristol Myers Squibb
1 program
bamlanivimab 7000mgPHASE_2_3
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
bamlanivimab 7000mgPHASE_2_3
Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
bamlanivimab 7000mgPHASE_2_31 trial
Active Trials
NCT04518410Completed4,044Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CureVacCVnCoV Vaccine
CureVacCVnCoV Vaccine
CureVacCVnCoV Vaccine
BioconEQ001
Brii Biosciencesbamlanivimab 7000mg
Senhwa BiosciencesSilmitasertib
CureVacCVnCoV 6 μg
Syndax PharmaceuticalsSNDX-6352
Gylden PharmaPepGNP-COVID19
AbelZeta PharmaMesenchymal stem cell exosomes
SandozRuxolitinib
CelularityCYNK-001
OsivaxOVX033
Gylden PharmaLD Vehicle-GNP
BioTherapeutics IncEIDD-2801

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 75,887 patients across 22 trials

NCT04838847CureVacCVnCoV Vaccine

A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19

Start: Oct 2021Est. completion: Sep 20220
Phase 3Withdrawn
NCT04860258CureVacCVnCoV Vaccine

COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

Start: Apr 2021Est. completion: Sep 2021129 patients
Phase 3Terminated
NCT04674189CureVacCVnCoV Vaccine

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Start: Dec 2020Est. completion: Jun 20222,357 patients
Phase 3Completed
NCT04605926BioconEQ001

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

Start: Nov 2020Est. completion: Jun 20210
Phase 3Withdrawn
NCT04518410Brii Biosciencesbamlanivimab 7000mg

ACTIV-2: A Study for Outpatients With COVID-19

Start: Aug 2020Est. completion: Jun 20234,044 patients
Phase 2/3Completed
NCT04668209Senhwa BiosciencesSilmitasertib

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

Start: Jan 2021Est. completion: Oct 202231 patients
Phase 2Terminated
NCT04515147CureVacCVnCoV 6 μg

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Start: Sep 2020Est. completion: Feb 2022668 patients
Phase 2Completed
NCT04415073Syndax PharmaceuticalsSNDX-6352

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Start: May 2020Est. completion: Jul 20201 patients
Phase 2Terminated
NCT05633446Gylden PharmaPepGNP-COVID19

Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Start: Sep 2025Est. completion: Dec 2026110 patients
Phase 1/2Not Yet Recruiting
NCT04602104AbelZeta PharmaMesenchymal stem cell exosomes

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS

Start: Nov 2020Est. completion: Jan 202318 patients
Phase 1/2Completed
NCT04581954SandozRuxolitinib

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Start: Oct 2020Est. completion: Sep 2023185 patients
Phase 1/2Completed
NCT04365101CelularityCYNK-001

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Start: Sep 2020Est. completion: Feb 20237 patients
Phase 1/2Terminated
NCT06128382OsivaxOVX033

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Start: Jan 2024Est. completion: Nov 202448 patients
Phase 1Completed
NCT05113862Gylden PharmaLD Vehicle-GNP

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Start: Jan 2022Est. completion: Sep 202226 patients
Phase 1Completed
NCT04392219BioTherapeutics IncEIDD-2801

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

Start: Apr 2020Est. completion: Aug 2020130 patients
Phase 1Completed
NCT04276987AbelZeta PharmaMSCs-derived exosomes

A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia

Start: Feb 2020Est. completion: Jul 202024 patients
Phase 1Completed
NCT07221097Angeles TherapeuticsInvestigational IVD for coronaviruses

Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses

Start: Sep 2025Est. completion: Aug 20261,500 patients
N/ARecruiting
NCT04880668Innovation PharmaceuticalsAerosol Box

Impact of Aerosol Box Use on Healthcare Provider Contamination

Start: Jun 2021Est. completion: Dec 2021122 patients
N/ACompleted
NCT04572399Aytu BioPharmaUV Light Treatment

UVA Light Device to Treat COVID-19

Start: Oct 2020Est. completion: Dec 20205 patients
N/ACompleted
NCT04453527Akari TherapeuticsThe CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19

The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19

Start: May 2020Est. completion: May 202172 patients
N/ACompleted
NCT04342884Human BioSciencesCOVID-19 Community Research Partnership

COVID-19 Community Research Partnership

Start: Apr 2020Est. completion: May 202261,410 patients
N/ACompleted
NCT04321811Alliance PharmaceuticalsObservation of patients with known, suspected, or at risk for COVID-19 infection

Behavior, Environment And Treatments for Covid-19

Start: Mar 2020Est. completion: Mar 20215,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 75,887 patients
26 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.